CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Dec 27, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
CRL$345.80-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income (Loss) for fiscal years and
(in thousands, except per share amounts)
| Fiscal Year | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Service revenue | $3,250,099 | $3,304,138 | $3,440,019 |
| Product revenue | 765,283 | 745,851 | 689,390 |
| Total revenue | 4,015,382 | 4,049,989 | 4,129,409 |
| Costs and expenses | |||
| Cost of services provided (excluding amortization of intangible assets) | 2,314,760 | 2,345,781 | 2,295,983 |
| Cost of products sold (excluding amortization of intangible assets) | 377,347 | 372,387 | 330,870 |
| Selling, general and administrative | 743,073 | 751,003 | 747,855 |
| Amortization of intangible assets | 179,066 | 138,471 | 137,440 |
| Intangible asset impairment | 210,974 | — | — |
| Goodwill impairment | 165,000 | 215,000 | — |
| Operating income | 25,162 | 227,347 | 617,261 |
| Other income (expense) | |||
| Interest income | 4,940 | 8,575 | 5,196 |
| Interest expense | (107,029) | (126,288) | (136,710) |
| Other income (expense), net | (22,576) | (16,520) | 95,537 |
| Income (loss) before income taxes | (99,503) | 93,114 | 581,284 |
| Provision for income taxes | 42,660 | 67,823 | 100,914 |
| Net income (loss) | (142,163) | 25,291 | 480,370 |
| Less: Net income attributable to noncontrolling interests | 2,175 | 3,088 | 5,746 |
| Net income (loss) attributable to Charles River Laboratories International, Inc. | $(144,338) | $22,203 | $474,624 |
| Calculation of net income (loss) per share attributable to Charles River Laboratories International, Inc. common shareholders | |||
| Net income (loss) attributable to Charles River Laboratories International, Inc. | $(144,338) | $22,203 | $474,624 |
| Less: Incremental dividends attributed to noncontrolling interest holders | — | 11,906 | — |
| Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | $(144,338) | $10,297 | $474,624 |
| Earnings (loss) per common share | |||
| Basic | $(2.91) | $0.20 | $9.27 |
| Diluted | $(2.91) | $0.20 | $9.22 |
| Weighted-average number of common shares outstanding | |||
| Basic | 49,564 | 51,380 | 51,227 |
| Diluted | 49,564 | 51,628 | 51,451 |
| See Notes to Consolidated Financial Statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.